Arcutis Biotherapeutics (ARQT) Competitors $14.86 +1.29 (+9.51%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARQT vs. LEGN, NUVL, BPMC, ELAN, CYTK, TGTX, VKTX, BBIO, CRNX, and KRYSShould you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Legend Biotech (LEGN), Nuvalent (NUVL), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), BridgeBio Pharma (BBIO), Crinetics Pharmaceuticals (CRNX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Arcutis Biotherapeutics vs. Legend Biotech Nuvalent Blueprint Medicines Elanco Animal Health Cytokinetics TG Therapeutics Viking Therapeutics BridgeBio Pharma Crinetics Pharmaceuticals Krystal Biotech Legend Biotech (NASDAQ:LEGN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking. Is LEGN or ARQT more profitable? Legend Biotech has a net margin of -66.92% compared to Arcutis Biotherapeutics' net margin of -140.97%. Legend Biotech's return on equity of -29.69% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-66.92% -29.69% -19.45% Arcutis Biotherapeutics -140.97%-119.11%-45.95% Does the MarketBeat Community prefer LEGN or ARQT? Legend Biotech received 24 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 71.55% of users gave Legend Biotech an outperform vote while only 64.13% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformLegend BiotechOutperform Votes8371.55% Underperform Votes3328.45% Arcutis BiotherapeuticsOutperform Votes5964.13% Underperform Votes3335.87% Do insiders & institutionals believe in LEGN or ARQT? 70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, LEGN or ARQT? Legend Biotech has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Does the media prefer LEGN or ARQT? In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Legend Biotech. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 6 mentions for Legend Biotech. Arcutis Biotherapeutics' average media sentiment score of 1.06 beat Legend Biotech's score of 0.60 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate LEGN or ARQT? Legend Biotech presently has a consensus target price of $81.54, indicating a potential upside of 135.12%. Arcutis Biotherapeutics has a consensus target price of $15.50, indicating a potential upside of 4.31%. Given Legend Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Legend Biotech is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has stronger valuation and earnings, LEGN or ARQT? Arcutis Biotherapeutics has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$520.18M12.18-$518.25M-$0.95-36.51Arcutis Biotherapeutics$138.71M12.54-$262.14M-$1.79-8.30 SummaryLegend Biotech beats Arcutis Biotherapeutics on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyA conspiracy Trump won’t unsealNew documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARQT vs. The Competition Export to ExcelMetricArcutis BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.59B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-8.3010.75135.1817.54Price / Sales12.54287.861,228.03140.34Price / CashN/A56.6540.6537.95Price / Book15.815.394.884.92Net Income-$262.14M$152.04M$118.97M$225.78M7 Day Performance16.37%-4.32%15.73%-1.58%1 Month Performance57.58%2.80%15.69%6.67%1 Year Performance485.04%17.30%34.73%22.48% Arcutis Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARQTArcutis Biotherapeutics0.7957 of 5 stars$14.86+9.5%$15.50+4.3%+509.0%$1.59B$138.71M-8.30150Options VolumeNews CoverageLEGNLegend Biotech1.6722 of 5 stars$33.83-3.7%$81.54+141.0%-43.4%$6.18B$520.18M-36.971,800NUVLNuvalent2.3475 of 5 stars$86.65-0.2%$112.60+29.9%+9.7%$6.16BN/A-25.0340Positive NewsBPMCBlueprint Medicines2.9172 of 5 stars$95.39+2.4%$122.11+28.0%+9.7%$6.06B$249.38M-44.17640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.09-0.1%$16.75+38.5%-10.5%$5.98B$4.45B30.259,300CYTKCytokinetics3.9849 of 5 stars$49.17+1.1%$83.93+70.7%+32.5%$5.80B$3.22M-9.04250TGTXTG Therapeutics3.8183 of 5 stars$34.78+8.6%$40.67+16.9%+81.7%$5.41B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2798 of 5 stars$48.07+2.2%$106.75+122.1%+147.1%$5.36BN/A-51.5620BBIOBridgeBio Pharma4.7227 of 5 stars$27.86+1.3%$47.69+71.2%-29.3%$5.27B$217.77M-11.63400Analyst ForecastCRNXCrinetics Pharmaceuticals4.2142 of 5 stars$54.10+0.8%$70.82+30.9%+60.7%$5.02B$1.04M-14.39210Analyst ForecastShort Interest ↓Positive NewsKRYSKrystal Biotech4.3083 of 5 stars$171.57+4.8%$206.67+20.5%+46.0%$4.93B$50.70M92.45229 Related Companies and Tools Related Companies LEGN Competitors NUVL Competitors BPMC Competitors ELAN Competitors CYTK Competitors TGTX Competitors VKTX Competitors BBIO Competitors CRNX Competitors KRYS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARQT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
